Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH

References

• Zipfel PF, Hallstrom T, Riesbeck K. Human Complement Control and complement evasion by pathogenic microbes- Tipping the balance. Mol Immunol. 2013;56:152–160.
   PubMed Web of Science ®Google Scholar
• de la Torre BG, Albericio F. Albericio F the pharmaceutical industry in 2021. an analysis of FDA Drug approvals from the perspective of molecules. Molecules. 2022;27:1075. doi:10.3390/molecules27031075
   PubMed Web of Science ®Google Scholar
• Hillmen P, Lewis SM, Bessler M, Luzatto L, Dacie J. The natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–1258. doi:10.1056/NEJM199511093331904
   PubMed Web of Science ®Google Scholar
• Hill A, Kelly R, Hillmen P. Thrombosis in PNH. Blood. 2013;121(25):4985–4996. doi:10.1182/blood-2012-09-311381
   PubMed Web of Science ®Google Scholar
• Weitz IC, Ghods M, Rochanda L, et al. Eculizumab therapy results in sustained reduction in markers of hemostatic activation and inflammation and thrombocytopenia in patients with PNH. Thromb Res. 2012;2012:107. PMID: 22542362.
   Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–1847. doi:10.1182/blood-2007-06-094136
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117:6786–6792. doi:10.1182/blood-2011-02-333997
   PubMed Web of Science ®Google Scholar
• Loschi M, Porcher R, Barraco F, et al. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. Am J Hematol. 2016;91:366–370. doi:10.1002/ajh.24278
   PubMed Web of Science ®Google Scholar
• Lee JW, Kulasekarara AG. Ravulizumab for the treatment of paroxysmal Nocturnal Hemoglobinuria. Expert Opin Biol Ther. 2020;20(3):227–233. doi:10.1080/14712598.2020.1725468
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, Langemeijer S, et al. One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. Eur J Haematol. 2021;106(3):389–397. doi:10.1111/ejh.13564PMCID:PMC8246907
   PubMed Web of Science ®Google Scholar
• Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7):632–639. PMID: 24521109. doi:10.1056/NEJMoa1311084
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113:4094–4100. doi:10.1182/blood-2008-11-189944.13
   PubMed Web of Science ®Google Scholar
• Hill A, Rother RP, Arnold L, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica. 2010;95:567–573. doi:10.3324/haematol.2009.007229
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement Inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157. doi:10.3389/fimmu.2019.01157
   PubMed Web of Science ®Google Scholar
• Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol. 2013;735:155–172. doi:10.1007/978-1-4614-4118-2_10
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Luzzatto L, et al. Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab. N Engl J Med. 2010;363:2270–2272. doi:10.1056/NEJMc1010351
   PubMed Web of Science ®Google Scholar
• Apellis Pharmaceuticals Inc. EMPAVELITM (pegcetacoplan) injection, for subcutaneous use; 2021. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c23d89e9-b00b-4520-e053-2995a90a95af. Accessed September 5, 2022.
   Google Scholar
• Swedish Orphan Biovitrum AB (publ). ASPAVELI 1 080 mg solution for infusion; 2021. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/aspaveli. Accessed September 5, 2022.
   Google Scholar
• Wong RSM, Pullon HWH, Deschatelets P, et al. Inhibition of C3 with APL-2 results in normalisation of markers of intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2018;132:2314. doi:10.1182/blood-2018-99-110827
   Web of Science ®Google Scholar
• De Castro C, Grossi F, Weitz IC, et al. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematology. 2020;95(11):1334–1343. doi:10.1002/ajh.25960
   PubMed Web of Science ®Google Scholar
• Peter Hillmen P, Szer J, Weitz IC, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;394:1028–1037. doi:10.1056/NEJMoa2029073
   Google Scholar
• De la Tour RP, Szer J, Weitz IC, et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PEGASUS): 48 week follow- up of a randomised open lable phase 3 active comparator controlled trial. Lancet Haematol. 2022;e2022(9):e648–659.
   Google Scholar
• Usuki K. The evaluation of pegcetacoplan in paroxysmal nocturnal haemoglobinuria patients with aplastic anemia. 2nd annual ESH-EBMT translational conference; 2022.
   Google Scholar
• Wong RS, Navarro JR, Comia NS, et al. Efficacy and safety of pegcetacoplan treatment in complement-inhibitor naïve patients with paroxysmal nocturnahemoglobinuria: results from the phase 3 prince study. Blood. 2021;138(supp1):606. doi:10.1182/blood-2021-147493
   Google Scholar
• Ueda Y, Takamori H, Nishimura JI. Pegcetacoplan versus Eculizumab in PNH. N Engl J Med. 2021;385(18):1723–1724. PMID: 34706182.
   PubMedGoogle Scholar
• Weitz IC, Al-Adhami M, Min J, et al. Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan Show Improvements in D-dimer Normalization and Decrease in Incidence of Thrombosis EHA; 2022.
   Google Scholar
• Notaro R, Luzatto L, Notaro R. Breakthrough hemolysis in PNH with proximal or terminal complement inhibition. NEJM. 2022;387:2. doi:10.1056/NEJMra2201664
   Web of Science ®Google Scholar
• Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2021 FDA TIDES (peptides and oligonucleotides) harvest. Pharmaceuticals. 2022;15(2):222. doi:10.3390/ph15020222
   Web of Science ®Google Scholar